Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ascletis Strategy Begins To Reach Fruition In Deal With Alnylam For HCC Candidate

Jul 12 2012

Related Content

Alnylam's Liver Cancer RNAi Program Enters The Clinic

Apr 01 2009

Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model,

Apr 06 2011

Ascletis Opens Its $100 Million Wallet - Breaks Ground On China Facility, Sets Sights On In-Licensing

Oct 26 2011

U.S.-China Hybrid Ascletis Helps Forge Stronger Ties Between China And North Carolina

Jul 26 2011

Related Companies

Ascletis Pharma, Inc.

Alnylam Pharmaceuticals Inc.

Onyx Pharmaceuticals, Inc.

Bayer AG

Additional Topics

China Asia Pacific United States Deals Strategy Platform Technologies BioPharmaceutical

More from China

More from Focus On Asia

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window